Introduction
Haematopoietic cell transplantation using cells from a volunteer-unrelated donor (VUD) is an established therapy for a number of malignant diseases, which cannot be cured by chemotherapy alone. The importance of selecting an human leukocyte antigen (HLA)-matched donor to improve survival is established. [1] [2] [3] [4] [5] However, there remains uncertainty as to the degree of HLA matching that is required; whether single mismatches can be tolerated and whether permissive mismatches (that is those that do not result in a poor outcome) can be defined. It has also been shown that the impact of HLA matching may differ dependent on other clinical factors, for example single mismatches may be better tolerated in patients with advanced disease stage at transplant, 6 or in those in which T-cell depletion or reduced intensity conditioning 7 is included as part of the transplant protocol.
Current VUD selection algorithms define the optimal donor as matched by high-resolution typing for 8/8 or 10/10 HLA alleles (at HLA-A, -B, -C, -DRB1±-DQB1). Although matching for HLA-DQB1 is thought to be less critical than matching for the other four HLA loci, 1,2 most centres type for this gene before transplantation. Frequently, however, because of the absence of a full match, a donor may be selected who is a 9/10 (or 7/8) match.
HLA-DPB1 is the sixth classical HLA locus. Currently, this locus is not routinely typed for or included in donor selection strategies. However, the degree of matching for this locus has a significant impact on transplant complications. 4, [8] [9] [10] [11] This molecule resembles the other HLA molecules in its ability to stimulate allo-reactivity, which has been shown, for example, by the isolation of DPB1-specific T cells generated in patients posttransplant. [12] [13] [14] [15] However, this molecule may be subject to different evolutionary pressure to the other HLA molecules and, therefore, may mediate additional effects. 16, 17 In this study, we have examined the impact of DPB1 allele matching status on transplant outcome in the context of HLA matching status for all six classical HLA loci and disease status. Owing to the significantly increased incidence of relapse in DPB1-matched transplants, which has earlier been reported, we hypothesized that the impact of DPB1 matching status might differ dependent on the disease stage. We report here a number of novel observations, which strongly support the inclusion of DPB1 matching status into donor selection algorithms to improve clinical outcomes.
Materials and methods

Sample and data collection
Patients fulfilling the requirements for this study were identified from the database held by the Anthony Nolan Trust in London, UK. The Anthony Nolan Trust collects clinical outcome data on all UK VUD transplants (using an Anthony Nolan Trust donor) at 6 weeks, 3 months, 6 months and annually. In addition, research samples pre-transplant/donation are collected. A total of 488 patients from 28 centres were identified.
Patients and inclusion criteria
Patients were included in this analysis if (1) they had received an unrelated donor transplant for AML, ALL or CML; (2) highresolution typing for six HLA loci (patient and donor) was available and (3) clinical follow-up data were available. Early disease stage was defined as acute leukaemia in CR1 or CML in CP1, with all other patients defined as having late stage disease.
The individual institutional review boards of all of the contributing hospitals approved the protocols used. The appropriate permission was obtained and all patients and donors signed informed consent before transplant/donation.
Definitions and HLA matching
We divided the group into four cohorts: 318 patient/donor pairs were matched for 10/10 alleles (HLA-A, -B, -C, -DRB1, -DQB1). Of these, 89 were matched for DPB1 (10/10M)(12/12 matched) and 229 were DPB1 mismatched (10/10D).
A total of 170 patient/donor pairs were matched for o10/10 alleles (118 single and 52 multiple mismatches). Of these, 44 were matched for DPB1 (o10/10M) (12/12 matched) and 126 were DPB1 mismatched (o10/10D).
There was no significant difference in the incidence of mismatching for DPB1 in the 10/10 versus p9/10 cohorts or between patients with early and late stage disease.
All analyses were carried out considering DPB1 matching status in the GvH vector.
Statistical analyses
Relationships between categorical variables were analysed by w 2 analysis or Fisher's exact test. Overall survival was calculated by Kaplan-Meier analysis. Univariate analysis of overall survival was performed using the log-rank test and multivariate analysis by Cox regression. These tests were carried out using SPSS v11.0.4 (SPSS, Chicago, IL, USA). Cumulative incidence of nonrelapse mortality (NRM) was calculated by competing risks regression, with relapse as the competing risk. Relapse rate was calculated as a cumulative incidence by competing risks regression, with death in remission as the competing risk. Chronic GvHD was calculated as a cumulative incidence by competing risks regression, with death and relapse as the competing risk. These statistics tests were performed using R (Version 2.2, http://www.R-project.org), with competing risks calculated using the package 'cmprsk' (RJ Gray, Birmingham, UK).
Results
Patient and transplant characteristics
Patient and donor characteristics of the 488 transplant pairs are shown in Table 1 . Transplants were performed between September 1996 and March 2006.
Acute graft versus host disease
The incidence of acute graft versus host disease (aGvHD) in the whole group was 53% (233/439), grade II-IV in 125 (28%) and grade III/IV in 26 (6%). The incidence and severity of aGvHD were increased in pairs who were mismatched for one or more allele at HLA-A, -B, -C, -DRB1, -DQB1. For 10/10-matched pairs, the incidence of any aGvHD and grade III/IV aGvHD were 47 and 4%, respectively; this was 63 and 8% in those with a single mismatch and 68 and 13% in multiply mismatched pairs (P ¼ 0.003 and 0.043, respectively). Conversely, neither the incidence nor the severity of aGvHD was significantly different dependent on the matching status for DPB1 (Table 2a) .
Chronic graft versus host disease
The incidence of chronic graft versus host disease (cGvHD) was 39% at 3 years. This was significantly different dependent on the degree of HLA matching (P ¼ 0.001) ( Figure 1a ; Table 2b ). The impact was noted in pairs mismatched for alleles at HLA-A, -B, -C, -DRB1, -DQB1. Both single and multiple mismatches increased the risk significantly compared with no mismatch (3 years: 47, 51 and 34%, respectively; P ¼ 0.02).
DPB1 matching status also impacted on cGvHD. The lowest risk was in the 10/10M patients (23% at 3 years), which increased to 39% in the 10/10D patients (P ¼ 0.04). In the o10/ 10-matched group, a DPB1 mismatch increased the risk from 30 to 54% at 3 years (P ¼ 0.04).
In those with cGvHD, approximately one third had extensive disease. This was not significantly different dependent on the degree of HLA matching for any locus.
Relapse
The incidence of disease relapse in the group overall was 42 and 46% at 3 and 7 years, respectively. Relapse risk was significantly different dependent on the degree of HLA matching (P ¼ 0.01), and seemed to be due to DPB1 matching status rather than matching status for HLA-A, -B, -C, -DRB1, -DQB1.
The risk of relapse was highest in patients in which DPB1 was matched (3 years: 10/10M 54%, o10/10M 52%). In the 10/10D patients and the o10/10D patients, relapse at 3 years was 38 and 36%, respectively (Figure 1b ; Table 2b ). Thus, the decrease in disease relapse seen with a DPB1 mismatch was significant in the group overall (P ¼ 0.001) and in the 10/10-matched transplants (P ¼ 0.006) and seemed as a trend in the o10/10-matched group (P ¼ 0.09).
There was no significant difference in disease relapse between the group with early and late stage disease (at 3 years: 47 and 39%, respectively, P ¼ 0.16). However, the presence of cGvHD had a significantly protective effect on disease relapse in patients with late stage disease (at 3 years: 35 and 51% in those with or without cGvHD, respectively (P ¼ 0.01)). There was no significant effect in early stage disease.
Non-relapse-related mortality NRM in the whole population was 10, 33 and 42% at day 100, 1 and 3 years, respectively. This was significantly different dependent on the degree of HLA matching (P ¼ 0.05) (Figure 1c ; Table 2b ). The impact was noted in patients with donors mismatched for alleles at HLA-A, -B, -C, -DRB1, -DQB1 (P ¼ 0.02). NRM at 1 year in patients with multiple mismatches was significantly worse than in those with either no mismatches or a single allele mismatch (41 versus 25 versus 24%, respectively, P ¼ 0.02). However, there was no significant difference between patients with zero or one allele recipient/ donor mismatch.
DPB1 matching status impacted on NRM in a 10/10-matched setting: the lowest risk of NRM was in the cohort of 10/10M (1 year: 18%), which rose to 28% in the 10/10D (P ¼ 0.03). There was no significant difference in NRM in the o10/10-matched setting dependent on DPB1 matching status (P ¼ 0.31).
The causes of death were GvHD (24, 14%), infection (98, 57%) or other (50, 29%). This was not significantly different dependent on DPB1-matching status.
Survival
The median follow-up of survivors is 4.6 years (3 months-11 years). The overall survival in the cohort was 38 and 34% at 5 and 9 years, respectively, with event-free survival of 25 and 23% at the same time points. This was significantly different dependent on the degree of matching for HLA alleles (P ¼ 0.009) (Figure 1d ; Table 2b ). Survival in patients with multiple mismatches was significantly worse than those with either no mismatches or a single allele mismatch (5 years: 24, 40 and 38%, respectively, P ¼ 0.017).
Other factors resulting in a significantly improved survival in univariate analysis were patient younger than median age (30 years) (P ¼ 0.004); donor younger than median age (35 years) (P ¼ 0.02); patient cytomegalovirus seronegative (P ¼ 0.002); sex matched or male donor/female recipient combination (P ¼ 0.018); CML (P ¼ 0.019) and early stage disease (P ¼ 0.001). Multivariate analysis, including these factors, was performed ( Table 3) .
The presence of limited cGvHD was associated with a significantly improved survival, compared with those with either no or extensive cGvHD, both in the 10/10 HLA-matched (P ¼ 0.0005) and HLA-mismatched (P ¼ 0.021) cohorts.
10/10 matching
Overall, no significant impact of DPB1 matching status was seen in pairs matched for 10/10 alleles (P ¼ 0.13). However, we found a statistically significant survival advantage for patients with early stage disease who received DPB1-matched transplants (n ¼ 110 DP mismatch; n ¼ 46 DP match) (5 years: 63% with DPB1 match versus 41% with DPB1 mismatch; P ¼ 0.006), but no such advantage for those with late stage disease (n ¼ 108 DP mismatch; n ¼ 38 DP match) (Figures 2a and b) .
o10/10-matched pairs
There was a significant survival advantage to those who were DPB1 mismatched compared with matched (5 years: 39 versus 21%, P ¼ 0.008). We split this group further depending on single or multiple HLA mismatches (for HLA-A, -B, -C, -DRB1, -DQB1). In 9/10-matched pairs, the overall survival in the presence of a DPB1 mismatch was equivalent to that in a 12/12-matched transplant (5 years: 43%), significantly better than DPB1 impact dependent on stage and HLA matching BE Shaw et al survival in DPB1-matched patients (25%, P ¼ 0.05). In less well-matched pairs (o9/10), the presence of a DPB1 mismatch showed a trend towards improved overall survival (5 years: 29%) compared with DPB1 match (14%, P ¼ 0.07). The protective effect of DPB1 mismatching was significant in those with late stage disease (n ¼ 66 DP mismatch; n ¼ 20 DP match) (P ¼ 0.011), but less so in those with early disease stage (n ¼ 49 DP mismatch; n ¼ 22 DP match) (P ¼ 0.12) (Figures 2c  and d) . In multivariate analysis, the presence of a DPB1 mismatch was associated with a significant survival advantage (odds ratio 0.478; 95% confidence interval 0.30, 0.75; P ¼ 0.001) ( Table 3) .
Discussion
The results of this study stress the importance of considering the matching status of DPB1 in the context of the matching status for five classical HLA loci in determining the outcome of VUD haematopoietic cell transplantation for leukaemia. These novel observations have immediate clinical application in terms of selecting the best donor to result in significantly improved patient outcomes.
For most patients, a 10/10-matched donor will be sought, although it has been reported that in patients with late disease stage leukaemia, a single HLA mismatch (at HLA-A, -B, -C, -DRB1, -DQB1) may be tolerated with regards to overall survival. 6 Our data confirm this earlier report and extend the overall conclusions by adding HLA-DPB1 as a relevant locus. In patients with early stage leukaemia, there is a significant survival advantage to selecting a donor who is DPB1 matched in addition to being matched at the other five classical HLA loci. Therefore, in such patients, in which more than one matched donor is available, additional typing of the DPB1 allele should be undertaken. Conversely, in patients with late stage leukaemia who received a transplant from a 10/10-matched donor, there was no significant survival benefit attributable to DPB1 matching in this study, such that typing at the DPB1 locus in this setting may be less important.
The outcome in patients who receive a transplant from a donor who is less well HLA matched has been shown to be inferior to that in patients receiving a transplant from a wellmatched donor. [1] [2] [3] The data in this study are in general agreement with these findings, but we have made the important novel observation that mismatching for HLA-DPB1 in this setting significantly improves the overall survival in such patients. Remarkably, the long-term survival in the patients who had a single HLA-mismatched (9/10) donor and who were DPB1 mismatched was the same as the survival with 12/12-matched donors and superior to those with a 10/10-matched but Table 2 Outcomes at various time points dependent on HLA-matching status Abbreviations: aGvHD, acute graft versus host disease; cGvHD, chronic graft versus host disease; NRM, non-relapse mortality. 'F', numbers too few to report at this time point.
DPB1 impact dependent on stage and HLA matching BE Shaw et al DPB1-mismatched donor. This was significant in patients with late stage leukaemia, but a similar pattern was seen in patients with early stage leukaemia. This finding is highly relevant to clinical practice. Approximately one third of patients, lacking a sibling donor, receive grafts, which are mismatched for one or more HLA allele (at HLA-A, -B, -C, -DRB1, -DQB1) as a 10/10 allele-matched VUD is not available. 18 In many cases, multiple single allelemismatched donors are available and may be accepted by the transplant physician. As DPB1 is likely to be mismatched in Table 3 Multivariate analysis of factors affecting overall survival in HLA 10/10-matched and -mismatched pairs DPB1 impact dependent on stage and HLA matching BE Shaw et al 70-80% of donors, 10, 19, 20 the probability of finding a DPB1-mismatched donor, who conforms to other donor requirements (for example age, cytomegalovirus serostatus), is highly probable. Knowledge of DPB1 type within these pairs will allow selection of an HLA-DPB1-mismatched donor in preference to a matched one and should improve overall survival.
We speculate on the possible reasons that this effect should be more marked in patients who are mismatched for other HLA alleles than in those who are otherwise HLA matched. We have earlier postulated that DPB1 functions in a manner different to the other classical HLA molecules. DPB1 is expressed at a much lower level than the other HLA molecules on the cell surface and is up-regulated in situations of stress. 21 The original test by which DPB1 types were defined, the Primed Lymphocyte Test, relied on a response by re-stimulated cells, which have earlier been incubated with the stimulator cells. 22 It is, therefore, possible that the effects of DPB1 may be enhanced by upregulation on the cell surface in a situation in which other HLA mismatches are present. HLA-DPB1 matching has been shown to have an impact on the outcome in kidney re-transplants 23 in which multiple mismatches are present. An alternative explanation is that a direct graft versus leukaemia effect is being mediated by peptides derived from mismatched HLA molecules acting as minor histocompatibility antigens, either peptides from the DPB1 molecule being presented in the context of the other mismatched HLA loci or DPB1 itself presenting peptides derived from other mismatched HLA loci. 24, 25 Such mechanisms may be of particular relevance in transplant settings in which HLAmismatched donors are routinely used (for example cord blood units or haplo-identical donors), and performing similar analyses in such transplant recipients is warranted.
Recently, we and others have suggested that matching for HLA-DPB1 may be considered in different ways, that is whether mismatches are predicted to be 'permissive' or 'non-permissive' based on amino acid and/or epitope differences. 8, [26] [27] [28] [29] [30] [31] This study was not intended to consider mismatching in this way; however, we did not find the impact on clinical outcomes using the proposed functional matching algorithm 26 to be of greater significance than the allele matching presented here (data not shown). As earlier, a major difference between our dataset DPB1 match (n=20) Figure 2 (a-d) The impact of HLA-DPB matching on outcome dependent on the degree of HLA matching for 10 alleles and disease stage. HLA-DPB1 matching results in a significantly better outcome (in 10/10-matched pairs) transplanted in early (n ¼ 110 DP mismatch; n ¼ 46 DP match) (a) but not late disease stage (n ¼ 108 DP mismatch; n ¼ 38 DP match) (b). Conversely, HLA-DPB1 matching results in a significantly better outcome (in o10/10-matched pairs) transplanted in late (n ¼ 66 DP mismatch; n ¼ 20 DP match) (d) but not early disease stage (n ¼ 49 DP mismatch; n ¼ 22 DP match) (c).
DPB1 impact dependent on stage and HLA matching BE Shaw et al and others is the widespread use of T-cell depletion using Alemtuzumab. It is interesting that when considering 'permissive' mismatches, the clinical impact tends to be seen in GvHD, but not relapse, whereas a significant impact on relapse has been found when considering allelic mismatches. This may explain some of the differences noted between the studies, particularly with regards to the impact of DPB1 matching in early or late stage disease. Not all of the earlier studies have considered chronic GvHD as a clinic outcome. Here, we show the important effect of DPB1 matching status on cGvHD and the impact of this, in turn, on relapse risk. Further investigation in large datasets such as that from the International Histocompatibility Working Group (in which the impact of allelic and epitope matching can be analysed simultaneously) is warranted and ongoing. Although the significant reduction in disease relapse, which we originally reported in DPB1-mismatched pairs, 32 has now been confirmed in a number of studies, 4,9,10 the effect that this has had on the overall survival in patients has been less clear. Earlier, we and others have speculated that the lack of a significant impact on overall survival may be due to the increase in relapse-related deaths being balanced by an decrease in GvHD-related deaths (in DPB1-matched patients). An alternative explanation, suggested here, is that the impact of DPB1 differs dependent on the degree of HLA matching for the other five HLA loci and the disease status at transplant such that the impact that this locus has on outcome in the group overall cannot be appreciated. We recognize that this study may have limitations related to the heterogeneity of the cohort and to the relatively small size of some patient subgroups. In addition, the cohort consists predominantly of patients receiving a T-cell depleted transplant using bone marrow as the stem cell source. We need now to confirm these findings in other datasets, which include different transplant settings (for example, T-cell replete transplants) and larger patient numbers.
In conclusion, we report the novel observation that the impact of HLA-DPB1 matching on survival after VUD transplants diverges dependent on the disease stage and matching status for the other five HLA loci. These findings not only stress the importance of DPB1 typing pre-transplant, but also the need to include this locus in the retrospective analyses of transplant outcomes. We suggest that careful consideration of DPB1 matching status before transplant may significantly improve the outcome of patients receiving grafts from both matched and mismatched unrelated donors.
